Supreme Court Shuns Pfizer Appeal in Neurontin Cases
The high court declined on Monday to take up Pfizer Inc.'s challenge to a $142 million jury verdict and continued litigation stemming from the company's off-label marketing of the epilepsy drug Neurontin.
This premium content is reserved for American Lawyer subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now